ArticleCancer cell2018
Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
158 citing papers in PubMed, 1 synthesis or guideline pooled it, 272 citations in OpenAlex.
- Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers.Nature genetics · 2025Pooled it
- Clinical translation of senescence-related pan-cancer multi-omics: tools for assessment and immunotherapy prediction.Cancer gene therapy · 2026Article
- Article
- Integrative Transcriptomic Analysis Identifies Hypoxia-responsive Cell Cycle Hub Genes as Prognostic Markers in Glioblastoma.Annals of neurosciences · 2026Article
- Integrative Transfer Network: Deep Transfer Learning Across Populations and Prediction Targets.bioRxiv : the preprint server for biology · 2026Article
- AGPAT family members act as potential predictive biomarkers and therapeutic targets in cervical cancer.Discover oncology · 2026Article
- Equitable Health Intelligence: An Open Benchmark of Multi-Population Machine Learning for Omics-Based Cancer Prognosis.bioRxiv : the preprint server for biology · 2026Article
- Omics-based Cancer Prognosis Across Ethnic Groups: From Feature Engineering to Disparity Detection and Mitigation.IEEE transactions on artificial intelligence · 2026Article
- Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan-cancer.Molecular oncology · 2026Article
- The Brazilian Population Tumor Atlas Project: addressing representation in cancer genomics in Brazil.Lancet regional health. Americas · 2026Review
- Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesis.EBioMedicine · 2026Article
- Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations.Cell reports · 2026Article
- Circulating cell-free DNA profiling reveals ancestry-dependent genetic variation in metastatic prostate cancer.Molecular biomedicine · 2026Article
- The impact of genomic ancestry on tumor genomics in head and neck squamous cell carcinoma.Cancer metastasis reviews · 2026Review
- Ethnic Disparities in Glioblastoma Markers: Impact of Chromosome 7 Gain and 10 Loss Alterations on Clinical Survival Outcomes.Oncology research · 2026Article
- AI-Guided Discovery of Oncogenic Signaling Crosstalk in Tumor Progression and Drug Resistance.Oncology research · 2026Review
- A Multi-Modal Transfer Learning Framework to Reduce Health Disparities in Prostate Adenocarcinoma.bioRxiv : the preprint server for biology · 2025Article
- Fast and sensitive detection of targeted gene fusions using frequency minimizers and fuzzy pattern matching with Fuzzion2.Cell reports methods · 2025Article
- Artificial intelligence in cancer: applications, challenges, and future perspectives.Molecular cancer · 2025Review
- Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer.NPJ breast cancer · 2025Article
98 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 10 institutions in 2 countries.
Jiao YuanCenter for Research on Reproduction & Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Zhongyi HuCenter for Research on Reproduction & Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Brandon A MahalDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Sihai D ZhaoDepartment of Statistics, University of Illinois at Urbana-Champaign, Champaign, IL 61801, USA.
Kevin H KenslerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.
Jingjiang PiResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Xiaowen HuCenter for Research on Reproduction & Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Youyou ZhangCenter for Research on Reproduction & Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Yueying WangCenter for Research on Reproduction & Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Junjie JiangCenter for Research on Reproduction & Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Chunsheng LiCenter for Research on Reproduction & Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Xiaomin ZhongCenter for Stem Cell Biology and Tissue Engineering, Department of Biology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, China.
Kathleen T MontoneDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Guoqiang GuanDepartment of Orthodontics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Janos L TanyiDepartment of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Yi FanDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Xiaowei XuDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Mark A MorganDepartment of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Meixiao LongDepartment of Internal Medicine, Division of Hematology, Ohio State University, Columbus, OH 43210, USA.
Yuzhen ZhangResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Rugang ZhangWistar Institute, Philadelphia, PA 19104, USA.
Anil K SoodCenter for RNA Interference and Non-coding RNA, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77584, USA.
Timothy R RebbeckDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.
Chi V DangWistar Institute, Philadelphia, PA 19104, USA; Ludwig Institute for Cancer Research, New York City, NY 10017, USA.
Lin ZhangCenter for Research on Reproduction & Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: linzhang@pennmedicine.upenn.edu.
University of Pennsylvania · USShanghai East Hospital · CNDana-Farber Cancer Institute · USHarvard University · USLudwig Cancer Research · USSun Yat-sen University · CNThe Ohio State University · USThe University of Texas MD Anderson Cancer Center · USThe Wistar Institute · USUniversity of Illinois Urbana-Champaign · US
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTherapeutic Micro RNA Strategies for Ovarian CancerP50CA083638 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI GODWIN, ANDREW K., GOLEMIS, ERICA A. · 1999 to 2013
$33.6MUNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0MTargeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0MTraining Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MNutritional Assessment of Cancer Risk in African MenU01CA184374 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2015 to 2019
$9.1MC-MYC TARGETS IN THE PATHOGENESIS OF HUMAN CANCERSR01CA057341 · NCI · WISTAR INSTITUTE · PI DANG, CHI V. · 1992 to 2021
$8.3MU.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2021
$7.9MMYC--TRANSCRIPTION AND INTERACTION WITH P107R01CA051497 · NCI · WISTAR INSTITUTE · PI DANG, CHI V. · 1995 to 2025
$5.3MEndothelial plasticity in glioma vascularization and therapy resistanceR01NS094533 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Yi Fan · 2015 to 2026
$4.3MMechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancerR01CA202919 · NCI · WISTAR INSTITUTE · PI Xi Chen, Rugang Zhang · 2016 to 2026
$4.1MNCI NIH HHS P30 CA010815NCI NIH HHS P50 CA083638NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA098258NCI NIH HHS P50 CA174523NCI NIH HHS P50 CA217685NCI NIH HHS R01 CA051497NCI NIH HHS R01 CA057341NCI NIH HHS R01 CA142776NCI NIH HHS R01 CA163377NCI NIH HHS R01 CA190415NCI NIH HHS R01 CA202919NCI NIH HHS T32 CA009001NCI NIH HHS U01 CA184374NINDS NIH HHS R01 NS094533
Abstract
Disparities in cancer care have been a long-standing challenge. We estimated the genetic ancestry of The Cancer Genome Atlas patients, and performed a pan-cancer analysis on the influence of genetic ancestry on genomic alterations. Compared with European Americans, African Americans (AA) with breast, head and neck, and endometrial cancers exhibit a higher level of chromosomal instability, while a lower level of chromosomal instability was observed in AAs with kidney cancers. The frequencies of TP53 mutations and amplification of CCNE1 were increased in AAs in the cancer types showing higher levels of chromosomal instability. We observed lower frequencies of genomic alterations affecting genes in the PI3K pathway in AA patients across cancers. Our result provides insight into genomic contribution to cancer disparities.
Indexed as
Black or African AmericanChromosomal InstabilityFemaleGenomicsHumansMaleMutationNeoplasmsPhosphatidylinositol 3-KinasesPolymorphism, Single NucleotideWhite PeoplePhosphatidylinositol 3-Kinasescancer disparitiescancer geneticscancer genomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.